Alkermes Plc SEC Filings

Alkermes plc furnished an update on its business, announcing financial results for the three and nine months ended September 30, 2025 and updating financial expectations for the year ending December 31, 2025.

The company made its press release and the investor presentation available as Exhibits 99.1 and 99.2, respectively, in connection with its conference call on October 28, 2025. The materials are furnished, not filed, under the Exchange Act.

Alkermes plc announced a recommended acquisition of Avadel Pharmaceuticals plc for $18.50 in cash per Avadel share, plus a non-transferable contingent value right (CVR) for a potential $1.50 per share cash payment upon specified milestones. The deal is expected to proceed via a court‑sanctioned scheme of arrangement under Irish law and would make Avadel a wholly owned subsidiary of Alkermes.

Completion is subject to customary approvals, including Avadel shareholder approval, Irish High Court sanction, registration of the court order, and required U.S. antitrust clearances, with completion expected in the first quarter of 2026. Alkermes entered a senior secured bridge term loan facility up to $1,231,459,813.22 to finance the cash consideration; financing is not a condition to closing. The CVR pays $1.50 per share if both FDA approval for the LUMRYZ indication and dismissal with prejudice of specified claims occur by December 31, 2028. The agreement includes customary no‑shop and fiduciary out provisions, an outside date of 9 months (extendable to 12 months for regulatory approvals), and an Avadel expense reimbursement cap of 1% of aggregate cash consideration.

Alkermes (ALKS): EVP R&D and Chief Medical Officer Craig C. Hopkinson reported insider transactions on 10/15/2025. He exercised 5,000 options at an exercise price of $19.34 and sold 9,000 ordinary shares at a weighted average price of $31.5307 (sold in multiple trades ranging from $31.51 to $31.60). Both the option exercise and the sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025. Following these transactions, he directly beneficially owned 73,740 ordinary shares; derivative securities beneficially owned were 45,104.

Joshua Reed, SVP and Chief Financial Officer, reported equity awards in a Form 4 filed for Alkermes plc (ALKS). On 10/08/2025 he was granted an employee stock option covering 158,743 ordinary shares with an exercise price of $31.51 and a restricted stock unit (RSU) award for 36,656 ordinary shares. Both awards were reported as acquired on the same date and are direct holdings. The option shares vest in four equal annual installments beginning 10/08/2026, and the RSUs vest on the same four-year schedule. Following the transactions, Mr. Reed beneficially owns 158,743 options and 36,656 RSUs. The Form 4 was signed on 10/10/2025.

Joshua Reed, Senior Vice President and Chief Financial Officer of Alkermes plc (ticker ALKS), submitted an initial Form 3 reporting his relationship to the issuer and stating that no securities are beneficially owned as of the reported event date. The filing cites the event date of 09/15/2025 and is signed on behalf of Mr. Reed by an attorney-in-fact, Shantale Greenson, on 09/23/2025. The form includes an exhibit listing a Power of Attorney (Exhibit 24.1) and contains standard Section 16(a) reporting information without disclosure of any direct or indirect holdings or derivative positions.

T. Rowe Price Associates, Inc. reported beneficial ownership of 10,041,900 shares of Alkermes plc common stock, representing 6.1% of the class as of June 30, 2025. The firm reports sole voting power for 9,983,207 shares and sole dispositive power for 10,041,900 shares on a Schedule 13G/A.

The filing identifies T. Rowe Price as an investment adviser filing under Rule 13d-1(b) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The Schedule is signed by Ellen York, Vice President, dated August 14, 2025.